Chronic renal allograft dysfunction: The evidence for a change in immunosuppression

Minerva Urologica e Nefrologica

Volumn 58, Issue 1, 2006, Pages 23-28

  Kingston, R W C ^a   Goldsmith, D J A ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Immunosuppression; Kidney allograft; Kidney failure

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOTHELIUM INJURY; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

CHRONIC DISEASE; DELAYED GRAFT FUNCTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 33745005273     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004;4:1289-95.
2. Shishido S, Asanuma H, Nakai H, Mori Y, Satoh H, Kamimaki I et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003;14:1046-52.
3. Mroz A, Lewandowski Z, Cieciura T, Matlosz B, Pazik J, Kwiatkowski A et al. C4d complement split product in the diagnosis of immunological activity of chronic allograft nephropathy. Transplant Proc 2006;38:97-10.
4. Gill JS, Tonelli M, Mix CH, Johnson N, Pereira BJ. The effect of maintenance immunosuppression medication on the change in kidney allograft function. Kidney Int 2004;65:692-9.
5. Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999;10:1136-44.
6. Smak Gregoor PJH, Sevaux RGL, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomised, prospective, multicentre study. J Am Soc Nephrol 2002;13:1365-73.
7. Abramowicz D, Manas D, Lao M, Vanrenterghem Y, Del Castillo D, Wijngaard P et al. Cyclosporine withdrawal from a mycophenolate mofetil containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002;74:1725-34.
8. Johnson RWG, Kreis H, Oberhauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001;72:777-86.
9. Pilmore HL, Dittmer ID. Calcineurin inhibitor nephrotoxicity: Reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clin Transplant 2002;16:191-5.
10. Irish W, Sherrill B, Brennan DC, Lowell J, Schnitzler M. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. Transplantation 2003;76:1686-90.
11. Toz H, Sen S, Sezis M. Comparison of tacrolimus and cyclosporine in renal transplantation by the protocol biopsies. Transplant Proc 2004;36:134-6.
12. Murphy GJ, Waller JR, Sandford RS, Furness PN, Nicholson ML. Randomised clinical trial of the effect of microemulsion cyclosporine and tacrolimus on renal allograft fibrosis. Br J Surg 2003;90:680-6.
13. Stoves J, Newstead CG, Baczkowski AJ, Owens G, Paraoan M, Hammad AQ. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Nephrol Dial Transplant 2004;19:2113-20.
14. Morris-Stiff GJ, Baboolal K, Dunstan F, Jurewicz WA. Conversion from cyclosporine (Neoral) to tacrolimus (Prograf) in renal allograft recipients with chronic graft nephropathy: results of an observational study. Transplant Int 1999;12:288-92.
15. Bakker RC, Hollander AA, Mallat MJ, Bruijn JA, Paul LC, de Fijter JW. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003;64:1027-34.
16. Mourad G, Vela C, Ribstein J, Mimran A. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 1998;65:661-7.
17. Merville P, Berge F, Deminiere C, Morel D, Chong G, Durand D. Lower incidence of chronic allograft nephropathy at 1 year post transplantation in patients treated with mycophenolate mofetil. Am J Transplant 2004;4:1769-75.
18. Gonzalez Molina M, Seron D, Garcia del Moral R. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study group of Chronic Allograft Nephropathy. Transplantation 2004;77:215-20.
19. Afzali B, Shah S, Chowdhury P, O'Sullivan H, Taylor J, Goldsmith D. Low dose mycophenolate mofetil is effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation 2005;79:304-9.
20. Morales JM, Wranmer K, Kreis H, Durand D, Campistol JM, Andres A et al., for the Sirolimus European Renal Transplant Study Group. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002;2:436-42.
21. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP et al. Long-term benefits with sirolimus based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004;15:809-17.
22. Stallone G, Infante B, Schena A, Battaglia M, Ditonno P, Loverre A et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005;16:3755-62.
23. Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and hisotological markers of chronic allograft nephropathy. Transplantation 2003;75:741-2.